Market Overview

Despite Weaker Industry Trends, BTIG Is Still Buying Brinker

Despite Weaker Industry Trends, BTIG Is Still Buying Brinker

BTIG maintains its Buy rating and $57 price target on Brinker International, Inc. (NYSE: EAT) despite cutting its same store sales estimate for Chili's due to weak industry trends.

Dallas, Texas-based Brinker operates casual dining restaurants under the Chili's Grill & Bar brand name and Maggiano's Little Italy brand.

Analyst Peter Saleh slashed his third quarter same store sales view of the company-owned Chili's to (1.0 percent) from (0.5 percent), hurt by weaker industry trends in March, and "likely continued sales weakness in oil-dependent markets."

However, the analyst maintained his third quarter EPS estimate of $1.00, which is above the consensus figure of $0.99, saying that modestly better margin performance and a lower share repurchase price could offset the weaker sales.

Saleh also keeps his 2016 EPS view of $3.55 unchanged, while consensus estimate calls for 2016 earnings of $3.56.

Related Link: Darden Restaurants Slides After Q3 Report

Brinker sees FY16 EPS at $3.55–$3.65, but indicated that the third quarter EPS growth would be in the mid-single digits citing lower restaurant-level margin. The analyst expects restaurant-level margin to decline 100 bps on higher labor costs and moderately higher restaurant expenses.

Saleh maintains his Buy rating on the stock saying, "We continue to believe that Brinker's stock has limited downside given the double-digit free cash flow yield, low single-digit dividend yield and industry low P/E multiple."

Brinker was recently seen down 0.57 percent on the day, trading at $46.97.

Latest Ratings for EAT

Sep 2019Initiates Coverage OnBuy
Sep 2019DowngradesOverweightNeutral
Sep 2019UpgradesHoldBuy

View More Analyst Ratings for EAT
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas Price Target Reiteration Restaurants Top Stories Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (EAT)

View Comments and Join the Discussion!

The Benefits Of A Buyback ETF

Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains